QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Harnessing the power of Nordic real-world data: Quantify assesses the impact of pneumococcal conjugate vaccines (PCVs) in paediatric immunisation programmes in Denmark, Finland, Norway and Sweden!
Using 10 years of national surveillance data from four Nordic countries, Quantify Research in collaboration with Pfizer found that a substantial amount of vaccine-preventable invasive pneumococcal disease remains present in elderly populations, despite the inclusion of pneumococcal conjugate vaccines (PCVs) in paediatric national immunisation programmes. Further, the choice of PCV used in paediatric immunisation programmes was associated with differences in serotype distribution and disease incidence amongst older […]
Will patient prevalence play a larger role in TLV’s assessments?
That’s a possible conclusion to draw from Sweden’s HTA body The Dental and Pharmaceutical Benefits Agency, TLV‘s report published this week, on the topic of improving access to drugs for rare diseases.https://www.linkedin.com/company/tlv-the-dental-and-pharmaceutical-benefits-agency/
The pharmaceutical market has shifted in recent decades to a landscape where more highly specialized medicines are developed for small patient populations, with illnesses that often are severe. However, costs relating to drug development, manufacturing […]
New publication on Psoriatic Arthritis
In our latest publication in the Journal of Medical Economics, the cost-effectiveness of bimekizumab was assessed for the treatment of psoriatic arthritis in Sweden in collaboration with UCB and others.
According to Quantify Research co-author and payer expert Linnea Oldsberg, the present study “provides important new evidence for decision makers in Sweden to optimally allocate healthcare resources through the analysis of biologic and targeted synthetic DMARDs in PsA.”
Check […]
Quantify staff recharged!
? On Friday last week, Quantify Research held its annual fall kick-off in the beautiful city of #Stockholm! Full of energy and inspiration, we connected not only as colleagues, but as a vibrant, unified team celebrating many recent successes and getting ready to take on new and exciting challenges. ?
? It was an invaluable opportunity to learn, gain fresh perspectives, and get motivated. And of course…to have […]